These findings suggest that IDO could play a role in protecting HCC cells from anti-tumor T cell immunity, which could be an explanation for the inconsistent efficacy of anti-PDL1/anti-PD-1 monotherapy. The gene discussed is CD274; the disease is hepatocellular carcinoma.